Abstract: Provided is a display panel. The display panel is divided into a display region and a non-display region disposed on a periphery of the display region. The display panel includes: a plurality of touch units and a plurality of light-emitting devices that are within the display region; and a plurality of touch signal leads and a plurality of data signal leads that are within the non-display region, wherein the touch signal lead is electrically connected to the touch unit, and the data signal lead is electrically connected to the light-emitting device; wherein in the non-display region, a region where at least a portion of the touch signal leads are disposed and a region where the plurality of data signal leads are disposed are respectively on different sides of the display region.

Abstract: A display module includes a display panel and a peripheral region. The peripheral region includes a bendable fan-out region including a panel bonding portion and a driving chip; a flexible circuit board, including a first and a second conductive layers, and a substrate. The first conductive layer includes a first and a second bonding portions, and a connection portion; the second conductive layer is located on a side of the first conductive layer and at least partially overlaps with the first bonding portion; the first and the second conductive layers are connected through a via hole penetrating through the substrate; an end of the flexible circuit board is bonded to the panel bonding portion through the first bonding portion, and the second bonding portion is bonded to a control circuit board; and a conductive protection layer, covering the driving chip and connected to the second conductive layer.

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: Systems, methods, and computer-readable media are provided for performing post automatic exposure control (AEC) and automatic white balance (AWB) processing to improve video quality. In some examples, a computing device can obtain one or more statistics associated with one or more past image frames and one or more future image frames, the one or more past image frames being captured prior to a current image frame and the one or more future image frames being captured subsequent to the current image frame. The computing device can adjust, based on the one or more statistics, at least one of a brightness or a color of the current image frame to generate an adjusted image frame. The computing device can further output the adjusted image frame.

Abstract: A device for image capture comprises a memory and one or more processors coupled to the memory and configured to: receive, during a preview mode or a recording, a first image, generate a first saliency map indicative of relative saliency of different regions within the first image, wherein the relative saliency of the different regions is indicative of a likelihood of attracting viewer gaze, generate one or more additional images based on manipulating pixels in the first image, generate one or more additional saliency maps indicative of relative saliency of different regions within the one or more additional images, and determine, during the preview mode or the recording, a camera setting based on the first saliency map and the one or more additional saliency maps.

Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

Abstract: A device for image capture comprises a memory and one or more processors coupled to the memory and configured to: receive, during a preview mode or a recording, a first image, generate a first saliency map indicative of relative saliency of different regions within the first image, wherein the relative saliency of the different regions is indicative of a likelihood of attracting viewer gaze, generate one or more additional images based on manipulating pixels in the first image, generate one or more additional saliency maps indicative of relative saliency of different regions within the one or more additional images, and determine, during the preview mode or the recording, a camera setting based on the first saliency map and the one or more additional saliency maps.

Abstract: The present application provides a novel thyroid hormone ß receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the ß receptor agonist. The disease comprises, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, the liver disease (fatty liver, NASH, NAFLD, etc.), the cardiovascular disease (atherosclerosis, etc.), the thyroid disease (hypothyroidism, thyroid cancer, etc.), etc.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: A device for image capture comprises a memory and one or more processors coupled to the memory and configured to: receive, during a preview mode or a recording, a first image, generate a first saliency map indicative of relative saliency of different regions within the first image, wherein the relative saliency of the different regions is indicative of a likelihood of attracting viewer gaze, generate one or more additional images based on manipulating pixels in the first image, generate one or more additional saliency maps indicative of relative saliency of different regions within the one or more additional images, and determine, during the preview mode or the recording, a camera setting based on the first saliency map and the one or more additional saliency maps.

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to a steroid compound, a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokinetic (PK) performance, oral bioavailability, stability, safety, clearance rate, and/or metabolic performance and the like.

Abstract: Provided herein is compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: Disclosed in the present invention is a cysteine-modified antibody-toxin conjugate. The cysteine-modified antibody-toxin conjugate is characterized in that: the antibody is an antibody in which cysteine is inserted on a fixed point, and insertion sites of the cysteine comprising one or more of the following sites: a 110th site, a IIIth site and a 142th site of a light chain in a Kappa/?L light chain constant region, and a 254th site, a 255th site, a 258th, a 259th site, a 354th site, a 355th site, a 357th site, a 378th site, a 379th site, a 386th site, a 387th site or a 410th site of a heavy chain of a heavy chain constant region of an IgG antibody.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

Abstract: The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugate in the present invention can also have a higher drug loading (that is, each targeted reagent has more hydrophilic drug junctions), keeps a desired PK property and has a same or better activity in a body.